Considering the Experimental Use of Temozolomide in Glioblastoma Research

Considering the Experimental Use of Temozolomide in Glioblastoma Research

Temozolomide (TMZ) currently remains the only chemotherapeutic component in the approved treatment scheme for Glioblastoma (GB), the most common primary brain tumour with a dismal patient’s survival prognosis of only ~15 months. While frequently described as an alkylating agent that causes DNA damag...

Full description

Bibliographic Details
Main Authors: Verena J. Herbener, Timo Burster, Alicia Goreth, Maximilian Pruss, Hélène von Bandemer, Tim Baisch, Rahel Fitzel, Markus D. Siegelin, Georg Karpel-Massler, Klaus-Michael Debatin, Mike-Andrew Westhoff, Hannah Strobel
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Biomedicines
Subjects:
Glioblastoma
limitations of experimental systems
established cell lines
Temozolomide
Online Access:https://www.mdpi.com/2227-9059/8/6/151

Internet

https://www.mdpi.com/2227-9059/8/6/151

Similar Items